Alpha Profiles · Company Profile

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology.

https://registry.alpha.ac/companies/ars-pharmaceuticals-inc

Entity: Public listing published
Primary listing: NASDAQ: SPRY
Verification: Partially verified
Last reviewed: 2026-09-17T04:46:18.691255+00:00

Overview

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

7 public records

Alexander A. Fitzpatrick

Chief Legal Officer and Secretary

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Brian Dorsey

Chief Operating Officer

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Eric Karas

Chief Commercial Officer

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Justin Chakma

Chief Business Officer

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Kathleen D. Scott

Chief Financial Officer

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Richard Lowenthal

President and Chief Executive Officer

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Sarina Tanimoto

Chief Medical Officer

State: unconfirmed
Effective: From Apr 29, 2026
Confidence: 88%
Evidence: DEF 14A spry-20260429.htmApr 29, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 17, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.